Emergence Therapeutics
GermanyWho owns Emergence Therapeutics?
Emergence Therapeutics is a German Biotech company, now owned by Eli Lilly, which acquired it in 2023 from NRW.BANK, Gruenderfonds Ruhr and High-Tech Gruenderfonds (HTGF).
Hand-verified · updated 2026-07-03
Open JSON · CC-BY
Key facts
- ·Fully exited in 2023 to Eli Lilly.
- ·Average hold across 3 realized cycles: 4 years.
Ownership history
3 ownership periods · co-invest detected
NRW.BANK sold Emergence Therapeutics to Eli Lilly in 2023 after 4 years.
High-Tech Gruenderfonds (HTGF) sold Emergence Therapeutics to Eli Lilly in 2023 after 4 years.
Gruenderfonds Ruhr sold Emergence Therapeutics to Eli Lilly in 2023 after 4 years.
More from Gruenderfonds Ruhr I
Other portfolio companies in the same fund.
More PE-backed in Biotech
Comparable biotech deals from other GPs.
USQuestions
Who owns Emergence Therapeutics?
Emergence Therapeutics is now owned by Eli Lilly, which acquired it in 2023 from NRW.BANK, Gruenderfonds Ruhr and High-Tech Gruenderfonds (HTGF).
When did Eli Lilly acquire Emergence Therapeutics?
Eli Lilly acquired Emergence Therapeutics in 2023, buying from NRW.BANK, Gruenderfonds Ruhr and High-Tech Gruenderfonds (HTGF).
Who did Emergence Therapeutics sell to?
NRW.BANK, Gruenderfonds Ruhr and High-Tech Gruenderfonds (HTGF) sold Emergence Therapeutics to Eli Lilly in 2023 (Trade Sale).
Who has owned Emergence Therapeutics over time?
Emergence Therapeutics has been through 3 private-equity ownership periods: NRW.BANK · via NRW.Venture · 2019–2023 · sold to Eli Lilly · (Trade Sale); Gruenderfonds Ruhr · via Gruenderfonds Ruhr I · 2019–2023 · sold to Eli Lilly · (Trade Sale); High-Tech Gruenderfonds (HTGF) · via HTGF III · 2019–2023 · sold to Eli Lilly · (Trade Sale).